70 related articles for article (PubMed ID: 38596294)
1. microRNA-34a as a Therapeutic Agent against Human Cancer.
Saito Y; Nakaoka T; Saito H
J Clin Med; 2015 Nov; 4(11):1951-9. PubMed ID: 26580663
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-34a-5p: A pivotal therapeutic target in gallbladder cancer.
Oda T; Tsutsumi K; Obata T; Ueta E; Kikuchi T; Ako S; Fujii Y; Yamazaki T; Uchida D; Matsumoto K; Horiguchi S; Kato H; Okada H; Chijimatsu R; Otsuka M
Mol Ther Oncol; 2024 Mar; 32(1):200765. PubMed ID: 38596294
[TBL] [Abstract][Full Text] [Related]
3. The Optimal Outcome of Suppressing Ewing Sarcoma Growth
Li DF; Yuan Y; Tu MJ; Hu X; Li YZ; Yi WR; Li PC; Zhao Y; Cheng Z; Yu AM; Jian C; Yu AX
Front Oncol; 2020; 10():222. PubMed ID: 32161722
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoids impair bone formation of bone marrow stromal stem cells by reciprocally regulating microRNA-34a-5p.
Kang H; Chen H; Huang P; Qi J; Qian N; Deng L; Guo L
Osteoporos Int; 2016 Apr; 27(4):1493-1505. PubMed ID: 26556739
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
Ma S; Fu T; Zhao S; Gao M
Eur J Pharmacol; 2019 Jun; 852():42-50. PubMed ID: 30851271
[TBL] [Abstract][Full Text] [Related]
6. hsa-miR-34a-5p potentiates cytarabine-mediated cell cycle arrest in MDA-MB-231 cells: a novel combination therapy.
Noorolyai S; Baghbani E; Rahmani S; Shadbad MA; Montazami N; Jigari-Asl F; Vazirabad AF; Baradaran B
Pathol Res Pract; 2022 Aug; 236():154004. PubMed ID: 35834883
[TBL] [Abstract][Full Text] [Related]
7. [miR-34a-5p regulates viability, invasion and apoptosis of placental trophoblastic cells
Li Q; Xu J
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jan; 40(1):79-86. PubMed ID: 32376568
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention.
Giraldo NA; Drill E; Satravada BA; Dika IE; Brannon AR; Dermawan J; Mohanty A; Ozcan K; Chakravarty D; Benayed R; Vakiani E; Abou-Alfa GK; Kundra R; Schultz N; Li BT; Berger MF; Harding JJ; Ladanyi M; O'Reilly EM; Jarnagin W; Vanderbilt C; Basturk O; Arcila ME
Clin Cancer Res; 2022 Dec; 28(24):5359-5367. PubMed ID: 36228155
[TBL] [Abstract][Full Text] [Related]
9. miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions.
Huang HY; Lin YC; Cui S; Huang Y; Tang Y; Xu J; Bao J; Li Y; Wen J; Zuo H; Wang W; Li J; Ni J; Ruan Y; Li L; Chen Y; Xie Y; Zhu Z; Cai X; Chen X; Yao L; Chen Y; Luo Y; LuXu S; Luo M; Chiu CM; Ma K; Zhu L; Cheng GJ; Bai C; Chiang YC; Wang L; Wei F; Lee TY; Huang HD
Nucleic Acids Res; 2022 Jan; 50(D1):D222-D230. PubMed ID: 34850920
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
11. Extracellular vesicle-shuttled miRNAs as a diagnostic and prognostic biomarker and their potential roles in gallbladder cancer patients.
Ueta E; Tsutsumi K; Kato H; Matsushita H; Shiraha H; Fujii M; Matsumoto K; Horiguchi S; Okada H
Sci Rep; 2021 Jun; 11(1):12298. PubMed ID: 34112884
[TBL] [Abstract][Full Text] [Related]
12. miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer.
Martini S; Zuco V; Tortoreto M; Percio S; Campi E; El Bezawy R; Doldi V; Landesman Y; Pennati M; Zaffaroni N
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34072442
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic.
Li WJ; Wang Y; Liu R; Kasinski AL; Shen H; Slack FJ; Tang DG
Front Cell Dev Biol; 2021; 9():640587. PubMed ID: 33763422
[TBL] [Abstract][Full Text] [Related]
14. Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview.
Larghi A; Rimbaș M; Rizzatti G; Carbone C; Gasbarrini A; Costamagna G; Alfieri S; Tortora G
Semin Oncol; 2021 Feb; 48(1):95-105. PubMed ID: 33608132
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
